SPRY ARS Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-10 16:00
Why SPRY matters now
ARS Pharmaceuticals, Inc. (SPRY) is a US stock in Healthcare. The latest InvestLog snapshot shows $7.94 with +0.76% on the session and $788.5M in market capitalization; recent performance reads 1-month +34.59% and YTD -17.17%.
The latest financial table shown here is Q1 2026, with revenue of $22.7M, net income of $-60.6M, and EPS of $-0.61. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -18.3%.
The latest indexable market news headline is "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $25.50; recent insider activity includes Fitzpatrick Alexander A filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
15.63
P/S
9.68
EV/EBITDA
-5.36
DCF Value
$-4.41
FCF Yield
-18.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
77.1%
Operating Margin
-204.5%
Net Margin
-200.0%
ROE
-153.6%
ROA
-68.8%
ROIC
-85.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $22.7M | $-60.6M | $-0.61 |
| Q4 2025 | $28.1M | $-41.3M | $-0.42 |
| FY 2025 | $84.3M | $-171.3M | $-1.74 |
| Q3 2025 | $32.5M | $-51.2M | $-0.52 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$25.50
Target (Median)
$25.50
Target Range
$25.00 - $26.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.83
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.